MarginsXMarginsX
Home › Markets › Health Care › MNPR

Monopar Therapeutics Inc. (MNPR)

MNPR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$71.97
-0.04% on the day
Market cap
$487.7M
Small cap
Revenue · 2025
$0
Prior year not contiguous
Net income · 2025
-$13.7M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1645469/000143774926010025/0001437749-26-010025-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerMNPR on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2019
SEC CIK0001645469
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$0
Net income-$13.7M
Operating income-$16.7M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$61.8M
Total assets$140.7M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
39.6 months
$52.6M cash at September 30, 2026
Share count, 1 year
+1.4%
2025-10-31 to 2026-10-31 · +127.9% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
-$3.7M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"In October 2026, the Company analyzed its cash requirements through March 31, 2028, and has determined that, based upon the Company's current available cash and cash equivalents and investments, the Company has no substantial doubt about its ability to continue as a going concern."
10-Q 2026-11-12
Cash and burn$52.6M cash; operating cash flow -$4.0M a quarter.Report 2026-09-30
Shares outstanding6,776,773 (2026-10-31); 6,682,584 a year earlier; 14,866,400 three years earlier. 3y figure adjusted for split (1-for-5 overall).Cover page 2026-10-31
Reverse splits, 3 years1; latest 1-for-5 on 2024-08-13Source 2024-08-13
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBPM LLP, Santa Rosa, California, United StatesPCAOB Form AP 2026-04-03
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $105K, sold $3.8M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$6.2M-$6.2M$52.6MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
$0-$5.3M-$3.2M$52.8MNo debt tagsNeeds four quarters10-Q 2026-08-12
Q1 2026
2026-03-31
$0-$3.9M-$3.5M$52.5MNo debt tagsNeeds four quarters10-Q 2026-05-14
Q4 2025
2025-12-31
Not filed-$5.2M-$3.1M$61.8MNo debt tags$010-K 2026-03-27
Q3 2025
2025-09-30
Not filed-$3.4M-$2.4M$127.7MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2025
2025-06-30
Not filed-$2.5M-$1.1M$39.5MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q1 2025
2025-03-31
Not filed-$2.6M-$5.7M$39.7MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q4 2024
2024-12-31
Not filed-$10.9M-$2.0M$45.8MNo debt tags$010-K 2026-03-27

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
FORM 424B5
424B52025-09-24
Latest annual report
FORM 10-K/A
10-K/A2026-04-01
Latest quarterly / interim
FORM 10-Q
10-Q2026-11-12
Latest current report
FORM 8-K
8-K2026-11-12
Latest proxy
FORM DEFA14A
DEFA14A2026-04-30

Source: SEC EDGAR submissions feed, 539 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.8%
1 month-0.1%
3 months-34.8%
Year to date+10.3%
1 year-17.3%
From 52-week high-41.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
CAPRCapricor Therapeutics Inc.$8.30-12.91%$482.6M
NGNENeurogene Inc. Common Stock$23.30-2.63%$482.3M
PHATPhathom Pharmaceuticals Inc.$5.88-2.97%$478.0M
STTKShattuck Labs Inc.$4.66+0.21%$474.6M
AQSTAquestive Therapeutics Inc.$3.76-3.84%$472.6M
OCSOculis Holding AG$7.63-0.13%$469.9M
GYREGyre Therapeutics Inc.$4.39+1.86%$506.3M
LYELLyell Immunopharma Inc.$14.65+2.45%$469.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier